Connect with us


One in Eight Americans Are Using Weight-Loss Drugs


The utilization of GLP-1 drugs, such as Ozempic, Wegovy, and Mounjaro, has witnessed a notable uptick among adults in the United States. Recent survey data from KFF indicates that approximately 1 in 8 adults in the US has employed a GLP-1 drug at some point, with roughly 6% currently relying on a prescription. This translates to over 15 million individuals actively incorporating these medications into their treatment regimens for various purposes.

The escalating demand for GLP-1 medications has resulted in reported shortages by the US Food and Drug Administration (FDA) over the past year. Drug manufacturers have grappled with meeting the increasing demand, leading to supply challenges for medications like Ozempic, Wegovy, and Mounjaro. Novo Nordisk, the manufacturer of Wegovy, recently disclosed that the drug is being initiated by at least 25,000 individuals each week in the US, marking a significant surge in usage compared to previous months.

Diverse Applications and Off-Label Use


Although GLP-1 drugs were initially approved for conditions such as type 2 diabetes and heart disease, their applications have expanded beyond their intended use. According to the KFF survey, a substantial portion of adults has utilized these medications for weight loss purposes, despite them lacking specific approval for this indication. This off-label use underscores the growing interest in GLP-1 drugs as potential tools for managing obesity and achieving weight loss goals.

While GLP-1 drugs have demonstrated efficacy in various clinical settings, affordability remains a significant barrier to accessing these medications for many individuals. The high cost of these drugs, often exceeding $1,000 per month, poses a considerable financial burden, particularly for those without adequate insurance coverage. Even among those with insurance, a majority of respondents reported difficulty affording these medications, highlighting the pressing need for policy changes to address affordability issues and ensure equitable access to essential treatments.

Regulatory Concerns and Alternative Options


In response to the surging demand for GLP-1 drugs, concerns have emerged regarding the safety and regulation of compounded versions of these medications. The FDA has cautioned against the use of compounded semaglutide due to potential risks associated with unregulated formulations. Additionally, the survey findings revealed that some individuals have sought alternative sources for obtaining GLP-1 drugs, including online providers and medical spas, raising questions about the safety, legality, and authenticity of such practices.

The findings of the KFF survey underscore the complex landscape surrounding the use of GLP-1 drugs in the US healthcare system. As policymakers and healthcare providers grapple with issues related to affordability, accessibility, and safety, there is a growing consensus among adults that changes are needed to improve access to these medications, particularly for weight loss purposes. 

Addressing these challenges will require collaborative efforts between stakeholders to ensure that individuals can access safe, effective, and affordable treatments for chronic conditions like obesity and diabetes. By prioritizing patient-centered approaches and implementing evidence-based policies, policymakers can work towards enhancing the quality of care and outcomes for individuals relying on GLP-1 drugs for their health and well-being.

Have you ever used weight loss drugs? What was your experience like? Leave your thoughts in the comments below.